MVMaria A. Vasilyeva

Maria A. Vasilyeva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria A. Vasilyeva has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Functional and anatomical outcomes of various perioperative treatment strategies for diabetic macular edema after cataract phacoemulsification

    by A.ZH. Fursova, M.A. Vasilyeva, A.S. Derbeneva, Yu.A. Karlash, F.K. Rabota

    Selecting the optimal perioperative treatment strategy for diabetic macular edema (DME) in patients undergoing cataract phacoemulsification remains an important clinical challenge. The effects of different approaches on changes in morphological OCT biomarkers remain insufficiently studied. Objective. The study aimed to compare the functional and anatomical outcomes of three perioperative strategies for DME treatment after cataract phacoemulsification. Material and methods. This retrospective cohort study included 102 patients (102 eyes) with type 2 diabetes mellitus, DME, and cataract. In group 1 (n=42), patients received preoperative anti-VEGF therapy followed by treatment according to the Treat-and-Extend regimen, group 2 (n=29) in addition to the same anti-VEGF regimen underwent intraoperative dexamethasone implantation, and group 3 (n=31) first underwent intraoperative dexamethasone implantation and then received anti-VEGF therapy. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), central choroidal thickness (CCT), fluid OCT biomarkers, hyperreflective foci, and the inter-injection interval were assessed. Results. BCVA improved significantly in all groups by month 12 of follow-up (from 0.22±0.12 to 0.64±0.17; p<0.001). The combined strategy provided the earliest reduction in CRT and CCT, rapid resolution of intraretinal and subretinal fluid, a decrease in the number of hyperreflective foci, and prolongation of the inter-injection interval. With the DEX-first strategy, after a pronounced early effect, by month 6 DME had reactivated with loss of anatomical response. Conclusions. Despite comparable functional outcomes at 12 months, the perioperative strategies differed substantially in the speed of achieving and maintaining anatomical response. The combined strategy provided the most favorable trajectory of morphological response and the most effective control of the inflammatory and exudative activity of DME in the early postoperative period.

  • Subretinal fibrosis in neovascular age-related macular degeneration: risk factors, mechanisms of development, and current options for prevention and treatment

    by A.ZH. Fursova, M.A. Vasilyeva, A.S. Derbeneva, I.M. Amir, M.S. Tarasov, I.F. Nikulich, Yu.A. Karlash, E.R. Agamian

    The results of numerous randomized clinical trials and clinical practice have demonstrated the effect of angiogenesis inhibitors (anti-VEGF agents) on the activity and growth of the neovascular complex in neovascular age-related macular degeneration (nAMD). At the same time, a reduction in the risk of macular fibrosis has been demonstrated, with its incidence decreasing from 39—100% in the “pre-antiangiogenic era” to 20.4—61.4% during anti-VEGF therapy. The main factors determining the risk of subretinal fibrosis are disease activity, timing of treatment initiation, treatment regimen and regularity, and type of drug. Fluctuations in retinal thickness and volatility of specific fluid compartments lead to an increase in the volume of subretinal hyperreflective material (SHRM) and hinder complete restoration of ellipsoid zone integrity. Extensive investigation of the role of angiopoietin-2 (Ang-2) in the development of fibrosis has shown that it acts not only as a cofactor of angiogenesis but also as an independent regulator of fibrogenesis through vascular destabilization with increased VEGF-mediated permeability and exudation, activation of macrophages and microglia with production of TGF-β and CTGF, as well as cross-talk with classical fibrotic pathways. The synergistic action of Ang-2 and VEGF-A promotes subretinal scarring and underscores the high potential of bispecific therapy for improving clinical outcomes in patients with nAMD. Compensatory activation of Ang-2 during anti-VEGF monotherapy may sustain tissue remodeling, contributing to the development of treatment resistance. Preclinical studies in models of choroidal neovascularization and clinical data on the effectiveness of faricimab 6 mg through dual Ang-2/VEGF-A inhibition have demonstrated not only superiority in controlling exudation and resolving retinal edema, but also a targeted effect on preventing proliferation and the development of subretinal fibrosis, as evidenced by a significant reduction in SHRM volume — a key precursor of fibrotic changes.

  • Open Access

    Hyperreflective Focuses as a Biomarker of Optical Coherence Tomography in Retinal Diseases: Pathogenesis, Visualization, and Clinical Significance

    by A. Zh. Fursova, M. A. Vasilyeva, A. S. Derbeneva, I. M. Amir, M. S. Tarasov, I. F. Nikulich, Yu. A. Karlash, E. R. Agamian, A. Ж. Фурсова, М. А. Васильева, et al.

    The presented literature review is devoted to an important OCT biomarker of retinal diseases; hyperreflective foci (GRF); which are considered as a promising indicator of inflammatory processes and vascular disorders of the retina. The purpose is to clarify modern ideas about the nature and classification of hyperreflective foci as an important diagnostic marker. This is necessary to improve the accuracy of diagnosis and monitoring of the most common retinal diseases; as well as to develop personalized treatment approaches; including using artificial intelligence technologies in ophthalmology. GRFs are defined as discrete point or rounded structures with increased optical density; ranging in size from 20 to 100 microns; localized within the retinal layers or in the subretinal space. GRF is not a specific morphological feature; but a universal phenotype reflecting a wide range of pathophysiological processes. The article describes in detail the morphology of foci; the pathogenetic mechanisms of their formation; the prognostic role and differences in age-related macular degeneration; diabetic retinopathy; diabetic macular edema. The correct differential interpretation of GRF requires an integrated approach; including an analysis of medical history and risk factors; a detailed assessment of their localization and morphological characteristics; as well as consideration of concomitant OCT signs and multimodal imaging data. The integration of these parameters makes it possible to accurately determine the nature of hyperreflective foci; choose the optimal patient management tactics; and reasonably predict the course of the disease.

  • Ocular phenotype of prematurity: morphofunctional features and the role of retinopathy of prematurity

    by Anzhella Zh. Fursova, Фурсова Анжелла Жановна, Ulyana I. Rasstriga, Расстрига Ульяна Игоревна, Maria A. Vasilyeva, Васильева Мария Андреевна, Anna S. Derbeneva, Дербенева Анна Сергеевна

    Advances in perinatal medicine have led to an increase in the number of preterm infants whose ocular development continues outside the physiological conditions of the intrauterine period. Current evidence indicates that the long-term ophthalmic consequences of prematurity are not limited to the development of retinopathy of prematurity (ROP) and include interconnected alterations in foveal morphology, retinal microvasculature, choroid, refraction, ocular biometry, and visual function. This review presents the concept of the ophthalmological phenotype of prematurity, which unites the structural, vascular, optical-biometric, and functional features of the eye that form under the influence of premature birth, perinatal factors, the severity of ROP, and the treatment administered. Prematurity is shown to be an independent factor determining the long-term trajectory of ocular development, whereas ROP and its treatment methods act as modifiers of morphofunctional changes. Current concepts of impaired foveogenesis, microcirculation features, choroidal and optical-biometric phenotypes, persistent avascular retina, functional impairment, and late complications are reviewed. The proposed concept substantiates the need for a shift from follow-up focused solely on the regression of active ROP toward a long-term phenotype-oriented model of patient care with a comprehensive assessment of the structural, vascular, biometric, and functional characteristics of the eye.

  • Open Access

    Expanding the potential of microinvasive glaucoma surgery in real-world clinical practice

    by A. Zh. Fursova, Yu. A. Karlash, M. S. Vasilyeva, A. S. Derbeneva, A. R. Kalashnikova, I. F. Khe, А. Ж. Фурсова, Ю. А. Карлаш, М. А. Васильева, А. С. Дербенева, et al.

    PURPOSE . To analyze the effectiveness and safety of Preserflo microschunt implantation during the 12-month follow-up period. METHODS . Thirty patients (30 eyes) underwent surgery (14 men and 16 women; mean age, 55.8±15.3 years); among them 24 patients (80%) had moderate glaucoma, and 6 patients (20%) — advanced glaucoma. Before surgery, mean intraocular pressure (IOP) was 22.9±5.3 mm Hg, and the number of antihypertensive drugs used was 2.1±1.0. In 26 patients (86.67%) microshunt implantation was performed as the first surgery, in 6 cases (6 eyes, 20%) it was combined with cataract phacoemulsification and IOL implantation, and 4 patients (13.33%) had a history of glaucoma surgery; the average period after surgery was 2.3±1.2 years. All patients underwent a comprehensive ophthalmological examination before surgery, as well as at 1 and 7 days, and at 1, 3, 6 and 12 months postoperatively. Additionally, the patients underwent anterior segment OCT to determine the horizontal and vertical dimensions of the filtration bleb (FB) and the position of the microshunt tube in the anterior chamber. RESULTS . On postoperative day 1, IOP decreased by 49.78% to 11.5±1.2 mm Hg, remained stable throughout the follow-up period, and reached 12.7±1.8 mm Hg by month 12, corresponding to a 44.6% reduction from baseline. Complete success was achieved in 26 patients (86.67%) and partial success in 4 patients (13.33%). Hypotony ≤6 mm Hg during the first days after surgery was observed in one patient, a shallow anterior chamber was noted in one other case, no ciliochoroidal detachment was detected. The position of the drainage tube relative to the cornea and iris remained stable. In all cases, posterior diffuse FBs formed (their horizontal size increased from 1878.9±394.47 µm on day 1 to 2497±658.49 µm by month 12, vertical size — from 286.32±70.68 to 368.68±90.92 µm, respectively), which underwent transformation from multilayered to microcystic and avascular. CONCLUSION . Microshunt implantation, as a new minimally invasive subconjunctival filtration procedure, addresses an unmet need in glaucoma surgery by providing effective IOP reduction with a good safety profile and may be a method of choice in early and moderate glaucoma, as well as in some cases of advanced glaucoma.

  • The effect of angiogenesis inhibitor therapy on the risk of fibrosis formation in neovascular age-related macular degeneration and potential strategies for its prevention

    by A.ZH. Fursova, M.A. Vasilyeva, A.S. Derbeneva, I.M. Amir, M.S. Tarasov, I.F. Nikulich, Yu.A. Karlash, E.R. Agamian

    Numerous randomized clinical trials and real-world clinical practice have demonstrated the effect of angiogenesis inhibitors (anti-VEGF agents) on the activity and growth of neovascular complexes in neovascular age-related macular degeneration (nAMD), with a proven reduction in the risk of macular fibrosis, the incidence of which decreased from 39—100% in the “pre-antiangiogenic era” to 20.4—61.4% after introduction of anti-VEGF therapy. The main factors determining the risk of subretinal fibrosis are disease activity, time of therapy initiation, treatment regimen, its regularity, and the type of drug. Variations in retinal thickness and the volatility of specific fluid compartments lead to an increase in the volume of subretinal hyperreflective material (SHRM) and prevent full restoration of the integrity of the ellipsoid zone. Extensive research into the role of angiopoietin-2 (Ang-2) in the development of fibrosis has shown that it acts not only as a cofactor of angiogenesis but also as an independent regulator of fibrogenesis through vascular destabilization with increased VEGF-mediated permeability and exudation, activation of macrophages and microglia with the production of TGF-β and CTGF, and cross-talk with classical fibrotic pathways. The synergism between Ang-2 and VEGF-A stimulates subretinal scarring and highlights the high potential of bispecific therapy for improving clinical outcomes in patients with nAMD. Compensatory activation of Ang-2 during anti-VEGF monotherapy may support tissue remodeling, contributing to the development of treatment resistance. Preclinical studies in models of choroidal neovascularization and clinical data on the effectiveness of faricimab 6 mg through dual Ang-2/VEGF-A inhibition have demonstrated not only superiority in controlling exudation and resolving retinal edema but also a targeted effect on preventing proliferation and the development of subretinal fibrosis, as confirmed by a significant reduction in the volume of SHRM — a key precursor to fibrotic changes.

  • New options determining the success of treatment for neovascular age-related macular degeneration

    by A.ZH. Fursova, I.F. Nikulich, M.A. Vasilyeva, A.S. Derbeneva, Yu.A. Karlash

    Neovascular age-related macular degeneration (nAMD) is a progressive retinal disease that can lead to severe and irreversible vision loss despite the availability of effective anti-VEGF agents. One of the potential causes of suboptimal treatment outcomes in nAMD is undertreatment, which may result from the need for frequent injections and follow-up visits, limitations in public healthcare funding, and challenges in achieving sustained and long-term control of disease activity (DA). Aflibercept 8 mg is a novel formulation with a higher concentration and improved molecular stability, enabling a fourfold increase in the molar dose of the active substance delivered to the vitreous body. The phase III PULSAR trial, a 96-week randomized, double-masked, active-controlled study, evaluated the efficacy and safety of 8 mg aflibercept compared with the standard 2 mg dose in treatment-naïve patients with nAMD. Participants were randomized 1:1:1 into three groups: aflibercept 2 mg every 8 weeks (2q8), 8 mg every 12 weeks (8q12), or 8 mg every 16 weeks (8q16) after three initial monthly loading doses. The study demonstrated the benefits of the 8 mg dose in extending interinjection intervals. By week 96, 88% of patients achieved an interval of ≥12 weeks, 71% ≥16 weeks, and 47% ≥20 weeks; in the 8q16 group, 53% of patients reached an interval of ≥20 weeks and 31% — 24 weeks. Over the 2-year period, patients in the 8q16 group received approximately 8 injections, compared to around 13 in the 2q8 group, with comparable anatomical and functional outcomes and no additional safety concerns. Given the proven effectiveness in improving best-corrected visual acuity (BCVA), superior outcomes in resolving intra- and/or subretinal fluid (IRF/SRF), and reduced treatment burden, it appears optimal to broadly transition patients already receiving aflibercept 2 mg to the higher molar concentration (aflibercept 8 mg) regardless of treatment phase or the interinjection interval. This approach aims to achieve a longer anti-VEGF effect duration and sustained DA control with the fewest possible injections.

  • Open Access

    Evaluation of the efficacy of surgical treatment of cataracts in patients with neovascular age-related macular degeneration

    by A. Zh. Fursova, E. I. Dmitrieva, M. A. Vasil’eVa, A. S. Derbeneva, Yu. A. Karlash, I. F. Nikulich, A. A. Atamanenko, M. S. Tarasov

    Purpose. To study of the effectiveness of cataract surgery based on the results of a comprehensive evaluation, including the patient's opinion about the state of visual functions, when assessed using a questionnaire before and after surgery.Material and methods. 117 patients (117 eyes) diagnosed with nAMD and cataract (LOCS I — 56 patients, 47.9 %; LOCS II — 57 patients, 48.7 %, LOCS III — 4 patients, 3.4 %), mean age 76.2 ± 5.7 years were included in the study. All patients received angiogenesis inhibitor therapy (aflibercept 2 mg), in Treat&Extend regimen. Cataract surgery was performed if disease activity is controlled. A questionnaire including 10 questions was developed to interview patients, 9 of which were assessed before, 1 and 6 months after cataract surgery, and a 10th question on patient satisfaction with the results of surgery — 1 and 6 months after cataract surgery.Results. There was a significant improvement in functional (increase in BCVA by 0.31 units from the baseline) and anatomical parameters (significant decrease in CRT, height of neuro- and pigment epithelium detachment), as well as in patients' assessment of vision-related quality of life. The most compromised aspect before surgery was the ability to read text in newspapers, books, and magazines. After surgery there was a significant improvement of the indicators characterizing the patient's adaptation to navigation and outside activities. There were minimal changes in central vision loss and metamorphopsia as assessed by patients (on average, by 0.02 b. and 1.21 b.). 99 patients (84.0 %) reported satisfaction with the results of the surgery. The strongest correlations (r = 0.94 and 0.81, p < 0.05) characterized the relationship between patients' evaluation of the effect of surgery and the presence of central vision spotting/loss of central vision, double vision.Conclusion. The results of surgery significantly contribute to the patient's assessment of his/her daily activities requiring clearer vision, primarily in the middle and far distances. Cataract surgery does not worsen the course of nAMD and, on the contrary, cataract surgery and continuation of antiangiogenic therapy contribute to a significant improvement in BCVA and anatomical improvement.

  • Hyperreflective focuses as a biomarker of multiple sclerosis progression

    by A. Zh. Fursova, M. Y. Zubkova, M. A. Vasilyeva, Y. A. Gamza, A. S. Derbeneva, I. F. Nikulich, N. A. Malkova, A. I. Prokaeva, P. N. Pozdnyakova

    Purpose: to identify the intraretinal hyperreflective foci (HRF), their specific characteristics, localization features and correlations with the duration of the disease, type of course and previous episodes of optic neuritis (ON) in multiple sclerosis (MS) patients using a high-resolution OCT scanning protocol. Materials and methods. The study included 160 patients (318 eyes) divided into 8 groups, i.e. Group 1: 44 eyes (13.84 %) — MS onset without a history of ON; Group 2: 30 eyes (9.43 %) — debut of MS with ON; Group 3: 56 eyes (17.61 %) — relapsing-remitting MS (RRMS) lasting ≤ 10 years without ON; Group 4: 38 eyes (11.95 %) — RRMS lasting ≤ 10 years with ON; Group 5: 49 eyes (15.41 %) — RRMS lasting ˃ 10 years without ON; Group 6: 37 eyes (11.63 %) — RRMS lasting ˃ 10 years with ON; Group 7: 34 eyes (10.69 %) — secondary progressive MS (SPMS) without ON; Group 8: 30 eyes (9.43 %) — SPMS with ON. Results. HRF were identified in all groups, at the levels of both the outer nuclear layer (ONL) and the inner nuclear layer (INL). Their number increased depending on the duration, type of course, and the presence of ON history. The thickness of the inner layers of the retina corresponded to the average normative indicators in the group with the onset of MS without ON. In the SPMS group after ON, a decrease in the total thickness of ganglions retinal cells layer (GCL) and the inner plexiform layer (IPL) was noted, showing minimal values of both avGCL + IPL (65.83 ± 8.27 μm) and avRNFL (76.37 ± 6.94 μm). High inverse correlations were revealed between avGCL + IPL and the amount of GRF at the levels of ONL and INL (-0.82 and -0.85, respectively, p = 0.01). Conclusions. The presence and quantity of HRF can be considered as a prognostic non-invasive biomarker associated with the duration of MS and the history of ON, allowing one to visualize the penetration of microglia activated by immune cells into the unmyelinated part of the central nervous system, helpful in elucidating their role in the pathogenesis and progression of the disease.

  • Optical coherence tomography in the diagnosis of multiple sclerosis

    by A.ZH. Fursova, M.YU. Zubkova, M.A. Vasilyeva, Yu.A. Karlash, I.F. Nikulich, A.S. Derbeneva

    Multiple sclerosis (MS) is a chronic autoimmune-inflammatory and neurodegenerative disease. PURPOSE This study explores the main structural changes in patients with MS and their relationships with the activity and type of disease course. MATERIAL AND METHODS This prospective study included 159 patients (318 eyes) with an established diagnosis of MS: group (44 eyes; 13.84%) — relapsing-remitting type MS (RRMS) lasting up to 1 year without a history of optic neuritis (ON); group 2 (30 eyes; 9.43%) — RRMS up to 1 year with ON; group 3 (56 eyes; 17.61%) — RRMS lasting from 1 to 10 years without ON; group 4 (38 eyes; 11.95%) — RRMS from 1 to 10 years with ON; group 5 (49 eyes; 15.41%) — RRMS >10 years without ON; group 6 (37 eyes; 11.63%) — RRMS >10 years with ON; group 7 (34 eyes; 10.69%) — secondary progressive multiple sclerosis (SPMS) without ON; group 8 (30 eyes; 9.43%) — SPMS with ON. Patients underwent standard ophthalmological examinations, including optical coherence tomography. RESULTS A decrease in structural parameters was diagnosed, progressing with the duration of the disease and the presence of ON: the minimum values of mGCL+IPL (65.83±9.14 μm) and mSNFL (76.37±14.77 μm) were detected in the group with SPMS with ON. High inverse correlations of EDSS with mGCL+IPL and mRNFL were demonstrated, with maximum in the group with the longest duration of MS without ON (–0.48 and -0.52 (p=0.01), respectively). CONCLUSION Changes in the thickness of the structural parameters of the retina, measured by OCT, can be considered as a predictor of the course of MS.